Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Lif… Read more
Genscript Biotech Corporation (GNNSF) - Total Assets
Latest total assets as of June 2025: $5.43 Billion USD
Based on the latest financial reports, Genscript Biotech Corporation (GNNSF) holds total assets worth $5.43 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genscript Biotech Corporation - Total Assets Trend (2013–2024)
This chart illustrates how Genscript Biotech Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genscript Biotech Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Genscript Biotech Corporation's total assets of $5.43 Billion consist of 15.8% current assets and 84.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.5% |
| Accounts Receivable | $118.72 Million | 2.3% |
| Inventory | $31.08 Million | 0.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.04 Million | 0.3% |
| Goodwill | $1.34 Million | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Genscript Biotech Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genscript Biotech Corporation's current assets represent 15.8% of total assets in 2024, a decrease from 46.0% in 2013.
- Cash Position: Cash and equivalents constituted 2.5% of total assets in 2024, down from 26.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 2.3% of total assets.
Genscript Biotech Corporation Competitors by Total Assets
Key competitors of Genscript Biotech Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genscript Biotech Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genscript Biotech Corporation generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Genscript Biotech Corporation generates $ 56.11 in net profit.
Genscript Biotech Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 4.15 | 3.80 |
| Quick Ratio | 1.90 | 4.06 | 3.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $576.28 Million | $ 1.68 Billion | $ 780.96 Million |
Genscript Biotech Corporation - Advanced Valuation Insights
This section examines the relationship between Genscript Biotech Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 55.8% |
| Total Assets | $5.28 Billion |
| Market Capitalization | $2.15 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Genscript Biotech Corporation's assets below their book value (0.41 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Genscript Biotech Corporation's assets grew by 55.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Genscript Biotech Corporation (2013–2024)
The table below shows the annual total assets of Genscript Biotech Corporation from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.28 Billion | +55.83% |
| 2023-12-31 | $3.39 Billion | +33.02% |
| 2022-12-31 | $2.55 Billion | +14.05% |
| 2021-12-31 | $2.23 Billion | +54.26% |
| 2020-12-31 | $1.45 Billion | +62.74% |
| 2019-12-31 | $889.41 Million | -3.01% |
| 2018-12-31 | $916.98 Million | +81.84% |
| 2017-12-31 | $504.26 Million | +123.09% |
| 2016-12-31 | $226.03 Million | +24.14% |
| 2015-12-31 | $182.07 Million | +97.09% |
| 2014-12-31 | $92.38 Million | +10.19% |
| 2013-12-31 | $83.83 Million | -- |